Additional capital brings total raised to $150 million in a Series C financing Funds support pivotal-stage development of Soficabtagene Geleucel, […]

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports manufacturing readiness for therapies with expedited clinical […]

— Breakthrough Therapy Designation granted to WU-CART-007 (Soficabtagene Geleucel “Sofi-cel”), an allogeneic CAR-T therapy for the treatment of T cell […]

Results from the Phase 1/2 Trial are a Foundation for the Ongoing Pivotal Study of Soficabtagene Geleucel for R/R T-Cell […]

— Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth, […]

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response […]

ST. LOUIS, MO and SAN DIEGO, CA, Feb. 26, 2025 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf […]

— Data Support Start of First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy in Pediatric and Adult […]

— First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy to Begin in First Quarter 2025 — — […]

ST. LOUIS, MO and SAN DIEGO, CA, Nov. 12, 2024 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf […]

— Researchers Shared Findings Including a Clinically Manageable Safety Profile and Anti-leukemic Activity with WU-CART-007 in Patients with R/R T-ALL/LBL […]

— Researchers to Present New Phase 2 Data Showing Safety and Anti-Leukemic Activity with WU-CART-007 and Additional New Findings for […]

The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract […]

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers […]

—   Dr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the Role   — ST. LOUIS, […]

— Positive trends continue as more patients receive treatment with WU-CART-007 in this study exploring the drug’s potential in improving […]

— Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T […]

— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability of WU-NK-101 in AML — […]

— WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events —  […]

— First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with […]

— Veteran biopharmaceutical executive Mark Alles brings more than three decades of global hematology and oncology experience, and significant corporate […]

— Cytokine-induced memory-like (CIML) NK cells engaged and activated endogenous adaptive immunity in the tumor microenvironment (TME) —  -WU-NK-101 demonstrated […]

— Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance — […]

— Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer — ST. LOUIS, MO and SAN DIEGO, CA, March […]

— WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors — –WU-NK-101 exhibited robust trafficking, intra-tumor infiltration, […]

— Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell […]

SAINT LOUIS, MO and SAN DIEGO, CA, November 10, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

— WU-NK-101’s differentiated memory natural killer (NK) expression profile supports enhanced anti-tumor activity and metabolic flexibility — — Data support […]

SAINT LOUIS, MO and SAN DIEGO, CA, November 3, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

SAINT LOUIS, MO and SAN DIEGO, CA, September 23, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

— WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic […]

Cell therapy veteran Natalie Mount, Ph.D., brings more than 25 years of industry experience ST. LOUIS, MO and SAN DIEGO, […]

ST. LOUIS, MO and SAN DIEGO, CA, July 19, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of […]

— WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment immunosuppression relative to conventional natural killer (NK) cells — […]

ST. LOUIS, MO and SAN DIEGO, CA, June 1, 2022- Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf […]

ST. LOUIS, MO and SAN DIEGO, CA, May 12, 2022 –Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of […]

ST. LOUIS, MO and SAN DIEGO, CA, April 7, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

ST. LOUIS, MO and SAN DIEGO, CA, March 24, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

— WU-CART-007 granted FDA Orphan Drug Designation for the treatment of patients with relapsed or refractory (R/R) T-cell acute lymphoblastic […]

ST. LOUIS, MO and SAN DIEGO, CA, March 9, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

WU-CART-007, an allogeneic off-the-shelf CAR-T cell therapy for T-Cell malignancies, has received IND clearance from the FDA   WU-CART-007 demonstrates […]

Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK) […]

ST. LOUIS, MO and SAN DIEGO, CA, November 10, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

ST. LOUIS, MO and SAN DIEGO, CA, November 9, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

ST. LOUIS, MO and SAN DIEGO, CA, November 4, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline […]

Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B […]

Biotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and […]

ST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) […]

ST. LOUIS, MO, March 2, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, […]

ST. LOUIS, March 1, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced […]

ST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today […]

ST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced […]

ST. LOUIS, Nov. 19, 2020 /PRNewswire/ — Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the […]

ST. LOUIS, April 30, 2019 /PRNewswire/ — Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced […]

ST. LOUIS, March 26, 2019 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the […]

ST. LOUIS, Feb. 20, 2019 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced data […]

ST. LOUIS, Dec. 3, 2018 /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced […]

ST. LOUIS, Nov. 13, 2018 /PRNewswire/ —  WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced […]

ST. LOUIS, Nov. 1, 2018  /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced […]